RJA
IOVA icon

Raymond James & Associates’s Iovance Biotherapeutics IOVA Stock Holding History

Raymond James & Associates’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-16,000
Closed -$115K – 3591
2020
Q1 		$115K Buy
+16,000
New +$424K ﹤0.01% 3189

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Raymond James & Associates's IOVA Position: Q3 2024 in Review

Raymond James & Associates reduced its Iovance Biotherapeutics (IOVA) stake by 12% in Q3 2024, selling an estimated $70.7K and leaving 52,456 shares worth $493K. The position accounts for ﹤0.01% of the portfolio, ranked #3121.

Raymond James & Associates first reported a position in IOVA in Q1 2016 and has held it in 24 quarters since. The position peaked at $1.56M in Q3 2020. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Raymond James & Associates held 52,456 shares of Iovance Biotherapeutics worth $493K as of Q3 2024.
  • Raymond James & Associates sold 7,463 Iovance Biotherapeutics shares in Q3 2024, an estimated $70.7K.
  • Iovance Biotherapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3121 holding.
  • Raymond James & Associates first reported a position in Iovance Biotherapeutics in Q1 2016 and has held it in 24 quarters since.
  • Raymond James & Associates's Iovance Biotherapeutics position peaked at $1.56M in Q3 2020.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.